Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

DOD - 9484 - Uniform Formulary Beneficiary Advisory Panel - Statutory (Congress Created)


Committee NameUniform Formulary Beneficiary Advisory PanelAgency NameDepartment of Defense
Fiscal Year2020Committee Number9484
Original Establishment Date10/5/1999Committee StatusChartered
Actual Termination Date Committee URL
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*15
Current Charter Date8/1/2020Designated Fed Officer Position Title*DFO
Date Of Renewal Charter8/1/2022Designated Federal Officer PrefixCol
Projected Termination Date Designated Federal Officer First Name*Paul
Exempt From Renewal*NoDesignated Federal Officer Middle NameJ.
Specific Termination AuthorityDesignated Federal Officer Last Name*Hoerner
Establishment Authority*Statutory (Congress Created)Designated Federal Officer Suffix
Specific Establishment Authority*10 U.S.C. § 1074g(c)Designated Federal Officer Phone*703-681-2890
Effective Date Of Authority*10/5/1999Designated Federal Officer Fax*
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*
Committee Type*Continuing
Committee Function*Scientific Technical Program Advisory Board


Agency Recommendation*Continue
Legislation to Terminate RequiredNo
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Panel will meet an estimate of four times a year to review and comment on the development of the Uniform Formulary by the DoD Pharmacy and Therapeutics Committee. The Director, Defense Health Agency is required to consider the comments of the panel before making his final decision.
How is membership balanced?*The Panel's membership includes family members of active duty and retired military personnel, members of retiree organizations, TRICARE healthcare contractors, and medical professionals from outside of DoD.
How frequent & relevant are cmte mtgs?*Per the Charter, the estimated number of Panel meeting is 4 per year. DoD implemented its Congressionally-mandated 3-tier Uniform Formulary (UF) in 2005 which required development of a transparent formulary management process that accesses medications for formulary status based on an evidence-based clinical and cost-effectiveness evaluation; open/equitable price competition; and to establish the Beneficiary Advisory Panel (BAP) which provides an opportunity for beneficiaries to comment on the DoD Pharmacy and Therapeutics (P&T) Committee's formulary recommendations before approval by the DHA Director. The BAP concept is unique to DoD. It provides transparency and credibility from a beneficiary perspective to the UF process.Unlike private sector health plans, the DoD uses more disclosure of the evidence presented and allows beneficiaries to provide input before implementation of formulary changes. A major focus of the BAP is the process of formulary decision implementation, especially the process of communication with the 9.7 million TRICARE beneficiaries. For example, the BAP can recommend a longer implementation period for medications moved to Non-Formulary (Tier 3) to balance between allowing necessary time for beneficiary notification versus cost considerations. Moreover, feedback from the BAP was instrumental in the DoD's decision to start sending targeted letters to affected beneficiaries during the up to 180-day implementation period. Implementation periods have been lengthened on several occasions supporting communication with beneficiaries.
Why advice can't be obtained elsewhere?*Mandated by law to review and comment on recommdenations by the DoD Pharmacy and Therapeutics Committee regarding DoD's Uniform Formulary.
Why close or partially close meetings?Meetings are not closed to the public unless the Department of Defense determines that items on the planned agenda meet the closed meeting provisions of 5 U.S.C. § 552b(c). Pursuant to DoD policy closed meetings can only be authorized by the DoD Sponsor (i.e., the Under Secretary of Defense for Personnel and Readiness), and only after consultation with the Office of the Department of Defense General Counsel.
Recommendation RemarksRegarding federal staff travel cost, the Defense Health Agency, HCO Pharmacy Operations Division has staff members assigned in San Antonio, Texas. Those staff members travel to and from the Panel's quarterly meeting to participate and present materials. The federal staff travel costs also include local travel for staff members. Title 10, U.S. Code, section 1074g(b), requires the Secretary of Defense to establish a Uniform Formulary Beneficiary Advisory Panel (BAP) under the Federal Advisory Committee Act. The estimated number of Panel meetings is four per year. The relationship between the committee and the decision maker is that no specific reports are submitted to the decision maker. Instead, the committee's advice and recommendations are communicated to the committee's decision maker through its meeting minutes. The committee's decision maker reviews these minutes and makes appropriate decisions for the Department of Defense.

Department of Defense (DoD) policy between fiscal year 2007 and 2011 required that subcommittee members be listed separately in the subcommittee section of GSA’s Database, even if they were duly appointed members of the parent committee. This policy, in some instances, caused a duplication of entries.

Beginning in fiscal year 2012, DoD will only list in the subcommittee section of GSA’s Database those who are appointed to just a subcommittee. If an individual is appointed to the parent committee and to one of the committee’s authorized subcommittees then his or her subcommittee affiliation will be reflected in the parent committee membership section of GSA’s Database.


Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*No
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchNoAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherNo
Outcome Increased Customer SatisfactionYesAction CommentNA
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*NoneDollar Value Of Grants Recommended$0.00
Cost Savings CommentThe recommendations made by the Panel do not attribute to a cost savings to the Department of Defense.Grants Review CommentNA
Number Of Recommendations*926Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe Panel made 45 recommendations during FY 2020. The Panel makes comments to the P&T Committee recommendations for changes to the Uniform Formulary, inplementation timelines, and prior authorization criteria. To date the Panel has made 926 recommendations. This included the 15 recommendation made in September 2019Access Agency WebsiteYes
% of Recs Fully Implemented*97.30%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe Director, Defense Health Agency, is required to consider the Panel's comments prior to his final decisions.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*2.70%Access PublicationsNo
% of Recs Partially Implemented CommentThe committee may recommed a shorter or longer implementation period. They may also reject a recommendation. The Director, Defense Health Agency makes the final decision.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*Minutes from the DoD Pharmacy & Therapeutics Committee and Uniform Formulary Beneficiary Advisory Panel are posted and available to Panel members.Narrative Description*The Uniform Formulary Beneficiary Advisory Panel provides a forum for input into the development and sustainment of the pharmacy benefit for all Department of Defense (DoD) beneficiaries.
Hide Section - COSTS


Payments to Non-Federal Members*$0.00Est Payments to Non-Fed Members Next FY*$0.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$35,000.00Estimated Payments to Federal Staff*$35,000.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$4,000.00Est Travel Reimb Non-Fed Members nextFY*$12,000.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$1,400.00Est. Travel Reimb to Fed Staff Next FY*$6,000.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$5,300.00Est. Other Costs Next FY*$12,480.00
Total Costs$45,700.00Est. Total Next FY*$65,480.00
Federal Staff Support (FTE)*0.40Est. Fed Staff Support Next FY*0.40
Cost RemarksThere was a decrease in cost due to COVID-19. Conducted business using virtual meeting for April 20, June 20 and Sept 20.Est Cost RemarksThe Panel plans to resume in-person meetings for FY21. However, this is dependent on the DOD travel restrictions and COVID-19
Hide Section - Interest Areas

Interest Areas

Food and Drugs
Food and Drugs
Medical Devices
Federal Government
Health Care
Health and Health Research
Veterans and Veterans' Medical Care


To View all the members, meetings and advisory reports for this committee please click here


No Documents Found



Data from Previous Years

ActionCommittee System IDCommittee NameFiscal Year
 COM-035673Uniform Formulary Beneficiary Advisory Panel2019
 COM-033051Uniform Formulary Beneficiary Advisory Panel2018
 COM-001402Uniform Formulary Beneficiary Advisory Panel2017
 COM-002905Uniform Formulary Beneficiary Advisory Panel2016
 COM-003453Uniform Formulary Beneficiary Advisory Panel2015
 COM-005027Uniform Formulary Beneficiary Advisory Panel2014
 COM-005560Uniform Formulary Beneficiary Advisory Panel2013
 COM-007120Uniform Formulary Beneficiary Advisory Panel2012
 COM-007758Uniform Formulary Beneficiary Advisory Panel2011
 COM-009300Uniform Formulary Beneficiary Advisory Panel2010
 COM-009824Uniform Formulary Beneficiary Advisory Panel2009
 COM-011188Uniform Formulary Beneficiary Advisory Panel2008
 COM-011697Uniform Formulary Beneficiary Advisory Panel2007
 COM-013062Uniform Formulary Beneficiary Advisory Panel2006
 COM-013538Uniform Formulary Beneficiary Advisory Panel2005
 COM-014948Uniform Formulary Beneficiary Advisory Panel2004
 COM-015497Uniform Formulary Beneficiary Advisory Panel2003
 COM-017126Uniform Formulary Beneficiary Advisory Panel2002
 COM-017455Uniform Formulary Beneficiary Advisory Panel2001
 COM-018944Uniform Formulary Beneficiary Advisory Panel2000